[go: up one dir, main page]

EP2970311A4 - BMP INHIBITORS AND METHODS OF USE - Google Patents

BMP INHIBITORS AND METHODS OF USE

Info

Publication number
EP2970311A4
EP2970311A4 EP14775808.0A EP14775808A EP2970311A4 EP 2970311 A4 EP2970311 A4 EP 2970311A4 EP 14775808 A EP14775808 A EP 14775808A EP 2970311 A4 EP2970311 A4 EP 2970311A4
Authority
EP
European Patent Office
Prior art keywords
methods
bmp inhibitors
bmp
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14775808.0A
Other languages
German (de)
French (fr)
Other versions
EP2970311A2 (en
Inventor
Asaf Alimardanov
Gregory D Cuny
Gurmit Singh Grewal
Arthur Lee
John C Mckew
Agustin H Mohedas
Min Shen
Xin Xu
Paul B Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
US Department of Health and Human Services
Original Assignee
Brigham and Womens Hospital Inc
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, US Department of Health and Human Services filed Critical Brigham and Womens Hospital Inc
Publication of EP2970311A2 publication Critical patent/EP2970311A2/en
Publication of EP2970311A4 publication Critical patent/EP2970311A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP14775808.0A 2013-03-14 2014-03-13 BMP INHIBITORS AND METHODS OF USE Withdrawn EP2970311A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361783695P 2013-03-14 2013-03-14
PCT/US2014/026042 WO2014160203A2 (en) 2013-03-14 2014-03-13 Bmp inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
EP2970311A2 EP2970311A2 (en) 2016-01-20
EP2970311A4 true EP2970311A4 (en) 2016-11-23

Family

ID=51625632

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14775808.0A Withdrawn EP2970311A4 (en) 2013-03-14 2014-03-13 BMP INHIBITORS AND METHODS OF USE

Country Status (4)

Country Link
US (2) US9682983B2 (en)
EP (1) EP2970311A4 (en)
JP (1) JP6542192B2 (en)
WO (1) WO2014160203A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8507501B2 (en) 2008-03-13 2013-08-13 The Brigham And Women's Hospital, Inc. Inhibitors of the BMP signaling pathway
EA026251B1 (en) 2010-09-01 2017-03-31 Томас Джефферсон Юниверсити Method for muscle repair and regeneration
CA2886187C (en) 2012-09-28 2020-04-14 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
US9682983B2 (en) 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
WO2016011019A1 (en) * 2014-07-15 2016-01-21 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
KR20180026459A (en) 2015-06-18 2018-03-12 세파론, 인코포레이티드 1,4-substituted piperidine derivatives
JP6986972B2 (en) 2015-06-18 2021-12-22 エイティナイン バイオ リミテッド Substituted 4-benzyl and 4-benzoylpiperidin derivatives
IL295440B1 (en) 2016-06-08 2025-01-01 Clementia Pharmaceuticals Inc Methods for treating heterotopic ossification
LT3971177T (en) 2016-07-20 2024-08-26 Novartis Ag Aminopyridine derivatives and their use as selective alk-2 inhibitors
EA039050B1 (en) 2016-11-16 2021-11-26 Клементиа Фармасьютикалс Инк. Methods for treating multiple osteochondroma (mo)
WO2018165569A1 (en) * 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Therapeutic compounds and methods
IL251949A0 (en) * 2017-04-26 2017-07-31 Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct Small organic molecules for use in the treatment neuroinflammatory disorders
CA3059232A1 (en) * 2017-04-27 2018-11-01 The Brigham And Women's Hospital, Inc. Novel alk2 inhibitors and methods for inhibiting bmp signaling
US10875861B1 (en) 2017-05-26 2020-12-29 Rutgers, The State University Of New Jersey Therapeutic compounds
WO2019178383A1 (en) 2018-03-14 2019-09-19 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
CN108586464A (en) * 2018-04-12 2018-09-28 苏州康润医药有限公司 A kind of synthetic method of 3- bromines pyrazolo [1,5- α] pyrimidine -6- formic acid
JP7504880B2 (en) * 2018-10-26 2024-06-24 ケロス セラピューティクス インコーポレイテッド Crystalline forms of ALK2 inhibitors
EP3875117A4 (en) 2018-10-31 2022-11-09 Senju Pharmaceutical Co., Ltd. Retinal ganglion cell death inhibitor
EP3886848A4 (en) 2018-11-27 2022-08-17 Rutgers, The State University of New Jersey PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS
CA3124088A1 (en) * 2018-12-20 2020-06-25 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
CN115956081A (en) 2020-06-12 2023-04-11 因赛特公司 Imidazopyridazine compounds having activity as ALK2 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135537A1 (en) * 2004-11-04 2006-06-22 Ronald Knegtel Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002510198A (en) 1997-05-16 2002-04-02 ザ プロクター アンド ギャンブル カンパニー Use of bone morphogenetic protein (BMP) receptor complex for screening
US6235741B1 (en) 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
WO1998054093A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
US6265403B1 (en) 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US20020041880A1 (en) 2000-07-05 2002-04-11 Defeo-Jones Deborah Method of treating cancer
AU2003298942A1 (en) 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
US7276525B2 (en) 2003-06-05 2007-10-02 Nippon Shinyaku Co. Ltd. Osteogenesis-promotion enhancer and method of screening the same
JP5066444B2 (en) 2004-03-29 2012-11-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ Use of phenothiazine derivatives for preventing and / or treating hearing loss
US20060063208A1 (en) 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
RU2285532C2 (en) 2004-10-28 2006-10-20 Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") Method for correction of toxic damages caused by doxorubicin
AU2006299338A1 (en) 2005-10-06 2007-04-12 Merck Sharp & Dohme Corp. Pyrazolopyrimidines as protein kinase inhibitors
GB0601638D0 (en) 2006-01-27 2006-03-08 Merck Sharp & Dohme Therapeutic treatment
DE602007004092D1 (en) 2006-03-22 2010-02-11 Vertex Pharma C-MET PROTEIN KINASE INHIBITOR FOR THE TREATMENT OF PROLIFERATIVE DISEASES
CA2657227A1 (en) 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
EP1900727A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
WO2008033408A2 (en) 2006-09-12 2008-03-20 The General Hospital Corporation Methods for identifying compounds that modulate cell signaling and methods employing such compounds
US8073681B2 (en) 2006-10-16 2011-12-06 Voicebox Technologies, Inc. System and method for a cooperative conversational voice user interface
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
KR101508797B1 (en) 2007-05-15 2015-04-06 오쓰까 세이야꾸 가부시키가이샤 Methods of using vasopressin antagonists in combination with anthracycline chemotherapeutic agents to reduce cardiac toxicity and / or improve survival
EP2572712A3 (en) 2007-06-01 2013-11-20 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
KR20100089090A (en) 2007-10-25 2010-08-11 아스트라제네카 아베 Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
AR070127A1 (en) 2008-01-11 2010-03-17 Novartis Ag PIRROLO - PIRIMIDINAS AND PIRROLO -PIRIDINAS
EP2231642B1 (en) 2008-01-11 2013-10-23 Novartis AG Pyrimidines as kinase inhibitors
JP2011511005A (en) 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 2-aminopyridine kinase inhibitor
US8507501B2 (en) 2008-03-13 2013-08-13 The Brigham And Women's Hospital, Inc. Inhibitors of the BMP signaling pathway
US8278105B2 (en) * 2008-09-09 2012-10-02 University Of Southern California Induction, propagation and isolation of liver progenitor cells
WO2010088735A1 (en) 2009-02-05 2010-08-12 Regenertech Pty Ltd Method of producing progenitor cells from differentiated cells
CN102596188A (en) * 2009-07-14 2012-07-18 贝思以色列女教会医学中心 Methods of increasing liver proliferation
WO2012100229A2 (en) 2011-01-21 2012-07-26 The General Hospital Corporation Compositions and methods for cardiovascular disease
WO2012115120A1 (en) * 2011-02-21 2012-08-30 国立大学法人 大阪大学 Method of preparing 5-ht neurons
US9505763B2 (en) * 2011-07-25 2016-11-29 Vanderbilt University Cancer treatment using BMP inhibitor
HUE047771T2 (en) 2011-09-15 2020-05-28 Hoffmann La Roche New dihydroquinoline-2-one derivatives
KR20130055216A (en) 2011-11-18 2013-05-28 롬엔드하스전자재료코리아유한회사 Novel organic electroluminescent compounds and organic electroluminescent device using the same
CA2899968C (en) 2013-02-02 2016-12-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Substituted 2-aminopyridine protein kinase inhibitor
US20160115167A1 (en) 2013-03-04 2016-04-28 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
US9682983B2 (en) 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
WO2014151761A1 (en) 2013-03-15 2014-09-25 Ariad Pharmaceuticals, Inc. Novel choline kinase inhibitors
EP3122355A4 (en) 2014-03-26 2017-08-09 The Brigham and Women's Hospital, Inc. Compositions and methods for inhibiting bmp
WO2016011019A1 (en) 2014-07-15 2016-01-21 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
EP3201187A4 (en) 2014-10-01 2018-04-11 The Brigham and Women's Hospital, Inc. Compositions and methods for inhibiting bmp

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135537A1 (en) * 2004-11-04 2006-06-22 Ronald Knegtel Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GREGORY D. CUNY ET AL: "Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 18, no. 15, 1 August 2008 (2008-08-01), AMSTERDAM, NL, pages 4388 - 4392, XP055283660, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2008.06.052 *
HONG C C ET AL: "Applications of small molecule BMP inhibitors in physiology and disease", CYTOKINE AND GROWTH FACTOR REVIEWS, ELSEVIER LTD, GB, vol. 20, no. 5-6, 1 October 2009 (2009-10-01), pages 409 - 418, XP026790610, ISSN: 1359-6101, [retrieved on 20091114] *

Also Published As

Publication number Publication date
US20160046633A1 (en) 2016-02-18
US10017516B2 (en) 2018-07-10
WO2014160203A3 (en) 2014-12-04
JP6542192B2 (en) 2019-07-10
EP2970311A2 (en) 2016-01-20
WO2014160203A2 (en) 2014-10-02
US20170334918A1 (en) 2017-11-23
JP2016515119A (en) 2016-05-26
US9682983B2 (en) 2017-06-20

Similar Documents

Publication Publication Date Title
EP2964651A4 (en) BMP INHIBITORS AND METHODS OF USE
EP2970311A4 (en) BMP INHIBITORS AND METHODS OF USE
EP2971000A4 (en) PHI-4 POLYPEPTIDES AND METHODS OF USE
EP2964235A4 (en) ANTIMICROBIAL-ANTIBIOFILM COMPOSITIONS AND METHODS OF USE
EP2967683A4 (en) ADAPTABLE INTERVERTEBRAL IMPLANT AND METHODS OF USE
EP3436048A4 (en) NEOANTIGENES AND METHODS OF USE
EP3390624A4 (en) MODIFIED TARGETED MODIFICATION POLYPEPTIDES AND METHODS OF USE
EP2969155A4 (en) MULTIBLOCK COPOLYMERS AND METHODS OF USE
EP2953457A4 (en) ERK INHIBITORS AND USES THEREOF
EP3317273A4 (en) EGFR INHIBITORS AND METHODS OF USE THEREOF
MA47849A (en) ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE
EP3319612A4 (en) OXYSTEOLS AND METHODS OF USE
EP2961382A4 (en) TOPICAL COMPOSITIONS AND METHODS OF USE
EP3394065A4 (en) TETRAHYDROPYRANYL-AMINO-PYRROLOPYRIMIDINONE AND METHODS OF USE THEREFOR
ME03063B (en) SUBSTITUTED SSAO 3-HALOGENOALLYLAMINE INHIBITORS AND USES THEREOF
EP2912178A4 (en) SUPER-ACTIVATORS AND METHODS OF USE THEREOF
EP2986623A4 (en) C3,3-DISUBSTITUTED 19-NOR-C21-N-PYRAZOLYL-STEROIDS AND METHODS OF USE THEREOF
HK1222803A1 (en) Combination therapy of antibodies and inhibitors
EP2882750A4 (en) DOT1L PROTEIN METHYLTRANSFERASE INHIBITORS AND METHODS OF USE
MA55097A (en) OXYSTEROLS AND METHODS OF USE THEREOF
EP2945647A4 (en) IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE
DK2970132T3 (en) ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF
EP2914575A4 (en) INHIBITORS OF PLASMINOGEN ACTIVATOR 1 AND METHODS OF USE
EP3985003C0 (en) DNA-PK INHIBITORS
MA42409A (en) OXYSTEROLS AND THEIR METHODS OF USE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151001

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SHEN, MIN

Inventor name: GREWAL, GURMIT, SINGH

Inventor name: YU, PAUL, B.

Inventor name: CUNY, GREGORY, D.

Inventor name: XU, XIN

Inventor name: MCKEW, JOHN, C.

Inventor name: ALIMARDANOV, ASAF

Inventor name: LEE, ARTHUR

Inventor name: MOHEDAS, AGUSTIN, H.

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/12 20060101ALI20160707BHEP

Ipc: A61P 31/10 20060101ALI20160707BHEP

Ipc: C07D 487/04 20060101AFI20160707BHEP

Ipc: A61P 5/30 20060101ALI20160707BHEP

Ipc: A61K 31/519 20060101ALI20160707BHEP

Ipc: A61P 33/00 20060101ALI20160707BHEP

Ipc: A61P 27/00 20060101ALI20160707BHEP

Ipc: A61K 31/5377 20060101ALI20160707BHEP

Ipc: A61P 29/00 20060101ALI20160707BHEP

Ipc: A61P 9/10 20060101ALI20160707BHEP

Ipc: A61P 31/04 20060101ALI20160707BHEP

Ipc: A61P 35/00 20060101ALI20160707BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20161020

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/10 20060101ALI20161014BHEP

Ipc: A61P 5/30 20060101ALI20161014BHEP

Ipc: A61P 27/00 20060101ALI20161014BHEP

Ipc: A61K 31/5377 20060101ALI20161014BHEP

Ipc: A61P 31/12 20060101ALI20161014BHEP

Ipc: A61P 9/10 20060101ALI20161014BHEP

Ipc: A61P 33/00 20060101ALI20161014BHEP

Ipc: A61P 29/00 20060101ALI20161014BHEP

Ipc: A61P 35/00 20060101ALI20161014BHEP

Ipc: A61K 31/519 20060101ALI20161014BHEP

Ipc: A61P 31/04 20060101ALI20161014BHEP

Ipc: C07D 487/04 20060101AFI20161014BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20171031

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20191203